Art. 31 Regulation (EU) 2016/161

Establishment of the repositories system

In forcesince 2 Oct 2015cited 5×
1.

The repositories system where the information on the safety features shall be contained, pursuant to Article 54a(2)(e) of Directive 2001/83/EC, shall be set up and managed by a non-profit legal entity or non-profit legal entities established in the Union by manufacturers and marketing authorisation holders of medicinal products bearing the safety features.

2.

In setting up the repositories system, the legal entity or entities referred to in paragraph 1 shall consult at least wholesalers, persons authorised or entitled to supply medicinal products to the public and relevant national competent authorities.

3.

Wholesalers and persons authorised or entitled to supply medicinal products to the public are entitled to participate in the legal entity or entities referred to in paragraph 1, on a voluntary basis, at no cost.

4.

The legal entity or entities referred to on paragraph 1 shall not require manufacturers, marketing authorisation holders, wholesalers or persons authorised or entitled to supply medicinal products to the public to be members of a specific organisation or organisations in order to use the repository system.

5.

The costs of the repositories system shall be borne by the manufacturers of medicinal products bearing the safety features, in accordance with Article 54a(2)(e) of Directive 2001/83/EC.

  • Gesetz über den Verkehr mit Arzneimitteln6467Law

    … die einen Datenspeicher einrichten oder verwalten, der zum Datenspeicher- und -abrufsystem nach Artikel 31 der Delegierten Verordnung (EU) 2016/161 der Kommission vom 2. Oktober 2015 zur Ergänzung der Richtlinie 2001/83/EG des …

  • Judgment of the Court (Seventh Chamber) of 26 January 2023. Consejo General de Colegios Oficiales de Farmacéuticos de España (CGCOF) v AdminDecisioninterprets

    … detailed rules for the safety features appearing on the packaging of medicinal products for human use, in particular Articles 25, 31, 32, 35, 36 and 44 thereof, must be interpreted as not precluding national legislation providing for the …

    26 Jan 2023 · 62021CJ0469

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Bayer Intellectual Property GmbH v kohlpharma GmbH.Decision

    Article 31(1) of the delegated regulation is worded as follows: ‘The repositories system where the information on the safety features shall be contained, pursuant to Article 54a(2)(e) of Directive [2001/83], shall be set up and managed …

    17 Nov 2022 · 62020CJ0204

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Novartis Pharma GmbH v Abacus Medicine A/S.Decision

    Article 31(1) of the delegated regulation is worded as follows: ‘The repositories system where the information on the safety features shall be contained, pursuant to Article 54a(2)(e) of Directive [2001/83], shall be set up and managed …

    17 Nov 2022 · 62020CJ0147

  • Règlement grand-ducal du 13 janvier 2019 modifiant : 1° le règlement grand-ducal modifié…iLaw

    … complété par l’alinéa suivant : « À la demande du ministre de la Santé , l’entité légale visée par l’article 31, paragraphe 1er, du règlement délégué (UE) 2016/161 de la Commission du 2 octobre 2015 complétant la …